Skip to main content
Midas Edge

Gossamer Bio, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2025233,677,057$24$1,321,303$(1,438,938)$(5,149)$(122,760)
Exercise of stock options211,460—220——220
Stock-based compensation——6,304——6,304
Issuance of common stock pursuant to Employee Stock Purchase Plan807,765—292——292
Net loss———(46,664)—(46,664)
Other comprehensive income————1,1251,125
Balance as of March 31, 2026234,696,282$24$1,328,119$(1,485,602)$(4,024)$(161,483)
Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income (loss) · Total stockholders' equity (deficit)
Shares · Amount
Balance as of December 31, 2024226,604,138$23$1,296,848$(1,268,568)$1,189$29,492
Exercise of stock options112,617—132——132
Stock-based compensation——2,405——2,405
Issuance of common stock pursuant to Employee Stock Purchase Plan504,507—372——372
Net loss———(36,638)—(36,638)
Other comprehensive loss————(2,013)(2,013)
Balance as of March 31, 2025227,221,262$23$1,299,757$(1,305,206)$(824)$(6,250)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.